{"slug":"nad-plus-trigeminal","verification":{"valid":true,"entries":2,"head":"ffd5ec51ec323b92f221ad9fa30e2cc8aeb7ad549b41987c831613386d9a999b"},"energy":{"passes":2,"tokens_in":30620,"tokens_out":2247,"tokens_total":32867,"cost_usd":0,"models":{"grok/grok-4.3":1,"owner":1},"head":"ffd5ec51ec323b92f221ad9fa30e2cc8aeb7ad549b41987c831613386d9a999b"},"provenance":[{"ts":"2026-06-30T01:39:58.363Z","model":"grok/grok-4.3","action":"write","prompt":"","input":"Write a data-first, evidence-graded article: NAD Plus for Trigeminal\nSlug: nad-plus-trigeminal\nAudience: readers researching peptide evidence for this specific condition or drug cross.\nRules: label every claim tier (human|preclinical|anecdotal|mechanistic|speculative). Separate human trials from rat studies from Reddit/X anecdotes. No medical claims. Repair-vs-suppression framing. register: source_ledger.\n\nENRICHMENT BRIEF (binding section logic — one ## per compound):\n{\"voice\":\"enrichment\",\"article_shape\":\"single_focus\",\"condition\":null,\"condition_key\":null,\"primary_peptide\":null,\"peptides_in_scope\":[{\"id\":\"nad-plus\",\"name\":\"NAD+\"}],\"drugs_in_scope\":[],\"weight_sensitive\":false,\"stimulant_context\":false,\"breaking_down\":{\"section_title\":\"What's breaking down\",\"degenerative_why\":[],\"degenerative_layers\":[],\"note\":\"No condition profile matched — infer degeneration layers from slug/title and ledger claims.\"},\"peptide_chains\":[{\"peptide\":\"nad-plus\",\"name\":\"NAD+\",\"section_title\":\"Why NAD+ might help you\",\"layer\":\"cellular energy\",\"steps\":[\"**Therefore for you:** If that layer is part of your problem, NAD+ is discussed because it targets repair (tissue) — not because it masks pain.\"],\"prose\":\"1. **Therefore for you:** If that layer is part of your problem, NAD+ is discussed because it targets repair (tissue) — not because it masks pain.\"}],\"drug_chains\":[],\"stimulant_chains\":[],\"stack_together\":\"Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\\n- **NAD+** → cellular energy\",\"section_headings\":[\"What's breaking down\",\"Why NAD+ might help you\",\"How these fit together\",\"What the evidence actually shows\",\"What scientists say\",\"What people say on Reddit\",\"What people say on X\",\"What we do not know\",\"Safety and limits\"],\"writer_rules\":[\"One ## section per compound in peptide_chains — do not merge into one peptide essay.\",\"Each Why section must use if-then steps from peptide_chains / dr","response":"{\n  \"slug\": \"nad-plus-trigeminal\",\n  \"title\": \"NAD+ for Trigeminal: Mitochondrial Repair in Nerve Pain Models\",\n  \"body\": \"## What's breaking down\\n\\nTrigeminal neuralgia involves sudden, severe facial pain from issues with the trigeminal nerve. Common layers include neurovascular compression causing nerve root distortion or atrophy, demyelination of afferents, elevated oxidative stress, and mitochondrial impairment in the trigeminal ganglion. These create hyperexcitability through altered ion channels and inflammatory signaling. Breakdown outruns natural repair when mitochondrial energy production drops, sustaining ectopic firing and sensitization.\\n\\n## Why NAD+ might help you\\n\\nNAD+ supports cellular energy production inside mitochondria. In the trigeminal ganglion, mitochondrial defects lower NAD+ levels and NAD+/NADH ratios, impairing the electron transport chain.\\n\\n1. If mitochondrial dysfunction sits in your pain pathway, boosting NAD+ with precursors like NR replenishes the pool.\\n2. Restored NAD+ activates Sirt1, which downregulates pain-related genes and inflammatory pathways.\\n3. Therefore for you: If that layer is part of your problem, NAD+ is discussed because it targets repair (tissue) — not because it masks pain.\\n\\n## How these fit together\\n\\nSingle-compound focus — NAD+ targets the cellular energy layer in trigeminal ganglion neurons.\\n\\n## What the evidence actually shows\\n\\nA 2025 mouse study used chronic constriction injury of the infraorbital nerve (CCI-IoN) to model trigeminal neuropathic pain. Researchers performed RNA-seq on the trigeminal ganglion and found broad downregulation of mitochondrial genes plus reduced NAD+ levels. NR supplementation raised NAD+, improved mitochondrial fitness, reduced mechanical allodynia, and worked mainly through Sirt1 to suppress inflammation and pain genes. This is preclinical (animal model) evidence only. No human trials specific to NAD+ or NR for trigeminal neuralgia appear in current searches. Broader r","tokens_in":30620,"tokens_out":2247,"cost":0,"prev":"genesis","hash":"62cd9027ac8c9b2469fb0a9847ba6d17c67212f19a664f39703aafa3584164ee"},{"ts":"2026-07-17T02:40:45.652Z","model":"owner","action":"voxel_divide","prompt":"","input":"nad-plus-trigeminal","response":"19 DIVs from body (verbatim, roundtrip-checked)","tokens_in":0,"tokens_out":0,"cost":0,"prev":"62cd9027ac8c9b2469fb0a9847ba6d17c67212f19a664f39703aafa3584164ee","hash":"ffd5ec51ec323b92f221ad9fa30e2cc8aeb7ad549b41987c831613386d9a999b"}]}